Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
1 "LASSO-Cox regression"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Article
Hematologic malignancy
Literature-Guided 6-Gene Signature for the Stratification of High-Risk Acute Myeloid Leukemia
Jong Keon Song, Dong Hyeok Lee, Hyery Kim, Sang-Hyun Hwang
Cancer Res Treat. 2025;57(4):1207-1217.   Published online January 24, 2025
DOI: https://doi.org/10.4143/crt.2024.1114
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Acute myeloid leukemia (AML) shows significant heterogeneity in therapeutic responses. We aimed to develop a gene signature for the stratification of high-risk pediatric AML using publicly available AML datasets, with a focus on literature-based prognostic gene sets.
Materials and Methods
We identified 300 genes from 12 well-validated studies on AML-related gene signatures. Clinical and gene expression data were obtained from three datasets: TCGA-LAML, TARGET-AML, and BeatAML. Least absolute shrinkage and selection operator–Cox regression analysis was used to perform the initial gene selection and to construct a prognostic model using the The Cancer Genome Atlas (TCGA) database (n=132). The final gene signature was validated with two independent cohorts: BeatAML (n=411) and TARGET-AML (n=187).
Results
We identified a six-gene signature (ETFB, ARL6IP5, PTP4A3, CSK, HS3ST3B1, PLA2G4A), referred to as the literature-based signature 6 (LBS6), that was significantly associated with lower overall survival rates across the TCGA (high-risk [HR], 4.2; 95% confidence interval [CI], 2.59 to 6.81; p < 0.001), BeatAML (HR, 1.52; 95% CI, 1.17 to 1.96; p=0.001), and TARGET (HR, 2.05; 95% CI, 1.36 to 3.08; p < 0.001) datasets. The high-LBS6 score group exhibited significantly poorer five-year event-free survival compared to the low-LBS6 score group (HR, 2.09; 95% CI, 1.38 to 3.15; p < 0.001). After adjusting for key risk factors, including gene mutations (WT1, FLT3, and NPM1), protocol-based risk group, white blood cell count, and age, the LBS6 score was independently associated with worse survival rates in validation cohorts.
Conclusion
Our literature-driven approach identified a robust gene signature that stratifies AML patients into distinct risk groups. The LBS6 score shows promise in redefining initial risk stratification and identifying high-risk AML patients.

Citations

Citations to this article as recorded by  
  • Integrated network propagation identifies prognostic metabolic signatures in acute myeloid leukemia
    Jong Keon Song, Hyery Kim, Sang-Hyun Hwang
    Journal of Translational Medicine.2025;[Epub]     CrossRef
  • 3,804 View
  • 176 Download
  • 1 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP